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Graphical Abstract
The Centers for Disease Control and Prevention (CDC) has received a record number of 
reports of tick-borne diseases in recent years. According to data from the National Notifiable 
Diseases Surveillance System, cases of tick-borne diseases increased more than twofold 
between 2004 and 2017, from 22,527 to 59,349, respectively.1 Tick-borne diseases now 
make up more than three-quarters of all vector-borne disease reports,2 and reports of tick-
borne rickettsial diseases, such as spotted fever rickettsioses (including Rocky Mountain 
spotted fever, ehrlichiosis, and anaplasmosis), account for 24% of these.1 Between 2016 and 
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2017, cases of spotted fever rickettsioses rose 46% (4,269 to 6,248), anaplasmosis rose 39% 
(4,151 to 5,762), and ehrlichiosis rose 19% (1,377 to 1,642).3 Incidence of tick-borne 
rickettsial diseases varies geographically in the United States and occurrence is seasonal—
most illness occurs in the spring and summer.4
Tick-borne rickettsial diseases often present as acute febrile illnesses with nonspecific 
clinical symptoms including headache, malaise, and arthralgia, and can range from mild to 
severe.4 Rocky Mountain spotted fever is the most severe rickettsial disease in the United 
States, with an estimated case fatality rate of 5% to 10%.5 Early treatment with doxycycline 
is essential for preventing death and severe illness from rickettsial diseases.6 In cases of 
Rocky Mountain spotted fever, delayed treatment beyond the fifth day of illness is the single 
most important predictor of fatal outcome.6
The CDC and American Academy of Pediatrics (AAP) recommend doxycycline as first-line 
treatment for people of all ages with suspected rickettsial disease.4, 7 Despite efforts to 
educate providers on the importance of clinical diagnosis and early treatment with 
doxycycline, misconceptions persist. According to a recent CDC study, only 53% of 
commercially insured patients diagnosed with any rickettsial disease between 2005 and 2016 
were prescribed doxycycline within 30 days of diagnosis.8
Misconceptions about treatment are even more evident among providers who treat the 
pediatric population. Children under the age of 10 years represent less than 6% of Rocky 
Mountain spotted fever cases, but 22% of deaths.5, 9 A 2012 survey of U.S. providers 
showed that only 35% believed doxycycline was the appropriate treatment for Rocky 
Mountain spotted fever in children younger than eight years of age; 80% correctly identified 
it as the preferred treatment in patients eight years and older.10 This discrepancy may 
contribute to the high mortality rate from Rocky Mountain spotted fever among children.
Historically, tetracycline antibiotics, including doxycycline, were contraindicated in children 
younger than eight years because of reports of tooth staining and enamel hypoplasia.10 
Recent studies have shown no tooth discoloration in children treated with short courses of 
doxycycline, and this finding has led to a change in pediatric recommendations regarding the 
drug: the 31st edition of the AAP’s Red Book now states that short courses of doxycycline 
are not likely to cause tooth staining or enamel hypoplasia and can be used in children of 
any age for less than 21 days.7 Moreover, the Red Book continues to highlight the vital 
importance of doxycycline as the treatment of choice in suspected rickettsial diseases in 
people of all ages.
To increase provider awareness of recommendations for diagnosis and treatment of Rocky 
Mountain spotted fever and other tick-borne diseases, the CDC has developed an online 
training toolkit (available at www.cdc.gov/rmsf/resources/toolkit.html) and learning module 
(available at www.cdc.gov/rmsf/resources/module.html). Providers can receive free 
continuing education and review information pertinent to the epidemiology, risk factors, 
clinical characteristics, treatment, and diagnosis of Rocky Mountain spotted fever and other 
U.S. tick-borne diseases. The toolkit includes (1) a narrated instructional video discussing 
clinical signs and symptoms, diagnosis, and treatment of Rocky Mountain spotted fever; (2) 
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a physician pocket card, which serves as a quick reference of key facts for clinical diagnosis 
and treatment of Rocky Mountain spotted fever; (3) a printable clinical timeline graphic to 
aid in the diagnosis of Rocky Mountain spotted fever; and (4) the Tickborne Diseases of the 
United States manual, which is a more detailed reference of clinical presentation, diagnosis, 
and treatment of tick-borne diseases. The hour-long learning module includes a rash 
comparison tool, which allows providers to test their knowledge of rashes, and two case-
based exercises.
Health care professionals can reduce morbidity and mortality from Rocky Mountain spotted 
fever and other tick-borne diseases through improved awareness, early recognition and 
diagnosis, and prompt treatment. For more information on other preventive measures, see 
Preventing Tick-Borne Diseases and visit www.cdc.gov/rmsf/index.html. ▼
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Preventing Tick-Borne Diseases
Before going outdoors.
• Know where to expect ticks: ticks live in grassy, brushy, or wooded areas, and 
even on animals.
• Treat clothing and gear: use products that contain 0.5% permethrin on boots, 
clothes, and camping gear.
• Use Environmental Protection Agency–registered insect repellents, such as 
DEET, picaridin, IR3535, oil of lemon eucalyptus, para-menthane-diol, or 2-
undecanone.
• Avoid contact with ticks: avoid wooded areas with high grass and walk in the 
center of trails.
After coming in from outdoors.
• Check your clothing for ticks.
• Examine gear and pets.
• Shower soon after being outdoors.
• Check your body for ticks: conduct a full body check and remove any ticks 
you find.
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